Skip to content

Study · Not a test of the peptide alone · 2023

4 results

Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission.

Figueredo Y, Cottone C, Ferreira T, Gonzalez J, Iacobellis G

Cureus29 Jan 2023Cited by 1 (Europe PMC)

PMID36865977 (opens in a new tab)PMCIDPMC9972903 (opens in a new tab)DOI10.7759/cureus.34331 (opens in a new tab)PepBankPUB-36865977
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Obesity is considered an independent risk factor for increased hospital length of stay and can be an obstacle to a safe discharge. Although typically prescribed in the outpatient setting, initiating glucagon-like peptide-one receptor agonists (GLP-1RAs) in the inpatient setting can be efficacious in reducing weight and increasing functional status. We report the use of GLP-1RA therapy with liraglutide and subsequent transition to subcutaneous semaglutide weekly in a 37-year-old female with severe obesity, weighing 694 lbs (314 kg) with a body mass index (BMI) of 108 kg/m2. Multiple medical and socioeconomic factors impaired the patient from being safely discharged and ultimately led to prolonged hospitalization. The patient received 31 consecutive weeks of GLP-1RA therapy in the inpatient setting along with a very low-calorie diet (800 kcal/day). Initiation and up-titration doses were completed using liraglutide for a total of five weeks. Subsequently, the patient was transitioned to receive weekly semaglutide and completed 26 weeks of therapy. At the end of week 31, the patient's weight decreased by 174 lbs (79 kg), or 25% of baseline weight, and BMI decreased from 108 to 81 kg/m2. GLP-1RAs offer a promising avenue for weight loss interventions in patients with severe obesity in addition to lifestyle modifications. The weight loss observed in our patient at the halfway point of the total treatment duration is a milestone in the pathway to gaining functional independence and meeting the criteria for future bariatric surgery. Semaglutide, a GLP-1RA, can be an effective intervention for severely obese patients with BMI greater than 100 kg/m2.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a 37-year-old woman with severe obesity, a sequence of liraglutide then semaglutide with a very low-calorie diet was followed by a weight loss of 174 lbs (25% of baseline) at week 31.

    In plain wordsIn one woman with severe obesity, weight fell by 174 lbs after liraglutide, then semaglutide, plus a very low-calorie diet.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change at week 31
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    174 lbs
    week 31
    Weight change
    25%
    week 31

    Source sentences

    Summary
    At the end of week 31, the patient's weight decreased by 174 lbs (79 kg), or 25% of baseline weight, and BMI decreased from 108 to 81 kg/m2.
    2 context sentences
    Summary · context
    We report the use of GLP-1RA therapy with liraglutide and subsequent transition to subcutaneous semaglutide weekly in a 37-year-old female with severe obesity, weighing 694 lbs (314 kg) with a body mass index (BMI) of 108 kg/m2.
    Summary · context
    The patient received 31 consecutive weeks of GLP-1RA therapy in the inpatient setting along with a very low-calorie diet (800 kcal/day).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a 37-year-old woman with severe obesity, BMI fell from 108 to 81 kg/m2 at week 31 of liraglutide then semaglutide therapy with a very low-calorie diet.

    In plain wordsIn one woman with severe obesity, BMI fell from 108 to 81 during treatment with two GLP-1 drugs and a very low-calorie diet.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI change at week 31
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    BMI
    81 kg/m2
    week 31

    Source sentences

    Summary
    At the end of week 31, the patient's weight decreased by 174 lbs (79 kg), or 25% of baseline weight, and BMI decreased from 108 to 81 kg/m2.
    2 context sentences
    Summary · context
    We report the use of GLP-1RA therapy with liraglutide and subsequent transition to subcutaneous semaglutide weekly in a 37-year-old female with severe obesity, weighing 694 lbs (314 kg) with a body mass index (BMI) of 108 kg/m2.
    Summary · context
    The patient received 31 consecutive weeks of GLP-1RA therapy in the inpatient setting along with a very low-calorie diet (800 kcal/day).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a 37-year-old woman with severe obesity, a sequence of liraglutide then semaglutide with a very low-calorie diet was followed by a weight loss of 174 lbs (25% of baseline) at week 31.

    In plain wordsIn one woman with severe obesity, weight fell by 174 lbs after liraglutide, then semaglutide, plus a very low-calorie diet.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at week 31
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    174 lbs
    week 31
    Weight change
    25%
    week 31

    Source sentences

    Summary
    At the end of week 31, the patient's weight decreased by 174 lbs (79 kg), or 25% of baseline weight, and BMI decreased from 108 to 81 kg/m2.
    2 context sentences
    Summary · context
    We report the use of GLP-1RA therapy with liraglutide and subsequent transition to subcutaneous semaglutide weekly in a 37-year-old female with severe obesity, weighing 694 lbs (314 kg) with a body mass index (BMI) of 108 kg/m2.
    Summary · context
    The patient received 31 consecutive weeks of GLP-1RA therapy in the inpatient setting along with a very low-calorie diet (800 kcal/day).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a 37-year-old woman with severe obesity, BMI fell from 108 to 81 kg/m2 at week 31 of liraglutide then semaglutide therapy with a very low-calorie diet.

    In plain wordsIn one woman with severe obesity, BMI fell from 108 to 81 during treatment with two GLP-1 drugs and a very low-calorie diet.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI change at week 31
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    BMI
    81 kg/m2
    week 31

    Source sentences

    Summary
    At the end of week 31, the patient's weight decreased by 174 lbs (79 kg), or 25% of baseline weight, and BMI decreased from 108 to 81 kg/m2.
    2 context sentences
    Summary · context
    We report the use of GLP-1RA therapy with liraglutide and subsequent transition to subcutaneous semaglutide weekly in a 37-year-old female with severe obesity, weighing 694 lbs (314 kg) with a body mass index (BMI) of 108 kg/m2.
    Summary · context
    The patient received 31 consecutive weeks of GLP-1RA therapy in the inpatient setting along with a very low-calorie diet (800 kcal/day).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.